What is the future of PARP inhibitors in cancer therapy?
Research is ongoing to expand the use of PARP inhibitors beyond BRCA-mutated cancers. Studies are exploring their efficacy in combination with other therapies, such as immunotherapy, chemotherapy, and radiotherapy. Additionally, new biomarkers are being investigated to identify patients who may benefit from PARP inhibitor treatment, even in the absence of BRCA mutations.
